After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Purchasing managers' surveys point toward a slowdown in U.K services and manufacturing
These 3 dividend stocks are rated a Hold by TheStreet
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
The pharmaceuticals company, led by CEO Joe Jiminez, had its first full quarter of generic competition for its Gleevec cancer drug.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.